This page shows the latest meningococcal B disease news and features for those working in and with pharma, biotech and healthcare.
The EU approval comes two-and-a-half years after Trumenba was green-lighted by the US FDA to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B, which is ... It is important to have multiple tools at our disposal to
Pfizer's Trumenba vaccine for meningitis B has shown favourable results in two phase III trials. ... Trumenba was approved by the FDA in 2014 to prevent invasive meningococcal disease caused by Neisseria meningitides serogroup B.
Trumenba - formerly known as rLP2086 - has been approved by the FDA to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B in people aged 10 to 25, a strain which ... Invasive meningococcal disease is a life-threatening
The ACIP recommendations now go to the Centers for Disease Control and Prevention (CDC) and Department of Health and Human Services (DHHS) for review and approval. ... Separately, Pfizer also said that the FDA has accepted its marketing application for
Aside from the risk of death, meningococcal B disease can also lead to long-term disabilities such as brain damage and hearing loss. ... The breakthrough therapy designation highlights the urgent need for prevention of meningococcal B disease," he added.
Multicomponent meningococcal serogroup B vaccine or 4CMenB (Bexsero, Novartis) was approved in the EU for the immunisation against invasive meningococcal disease (IMD) caused by the bacterium Neisseria meningitidis serogroup B in ... Looking ahead.
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Graphite is a digital agency which partners with globally respected pharma and healthcare organisations to create powerful digital experiences. We...